Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Launched by NOVARTIS PHARMACEUTICALS · Oct 7, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Visual impairment due to choroidal neovascularization (CNV) secondary to PM
- • Best corrected visual acuity (BCVA) in the study eye \> 24 and \< 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters
- • High myopia (\> -6D), anterior-posterior elongation \> 26 mm; posterior changes compatible with the pathologic myopia
- • Either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal
- Exclusion Criteria:
- • Patients with uncontrolled systemic or ocular diseases
- • Blood pressure \> 150/90 mmHg
- • History of pan-retinal, focal/grid laser photocoagulation or intraocular treatment with any anti-VEGF or vPDT in the study eye
- • Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye
- • Other protocol-defined inclusion/exclusion criteria may apply
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
München, , Germany
Bern, , Switzerland
Montreal, Quebec, Canada
Ankara, , Turkey
Berlin, , Germany
Hamburg, , Germany
Paris, , France
Belfast, , United Kingdom
Freiburg, , Germany
Regensburg, , Germany
Milano, Mi, Italy
Udine, Ud, Italy
Suita City, Osaka, Japan
Seoul, Korea, Korea, Republic Of
Seoul, , Korea, Republic Of
Wien, , Austria
Porto, , Portugal
Koeln, , Germany
Paris, , France
Vancouver, British Columbia, Canada
New Delhi, , India
Toulouse, , France
Firenze, Fi, Italy
Bunkyo Ku, Tokyo, Japan
Kyoto, , Japan
Reims, , France
Fukuoka City, Fukuoka, Japan
Hospitalet De Llobregat, Cataluña, Spain
Budapest, , Hungary
Debrecen, , Hungary
Sapporo City, Hokkaido, Japan
Vilnius, , Lithuania
Coimbra, , Portugal
Riga, , Latvia
Etlik / Ankara, , Turkey
Bordeaux Cedex, , France
Bari, Ba, Italy
Wolverhampton, , United Kingdom
Berlin, , Germany
Valladolid, Castilla Y Leon, Spain
Bonn, , Germany
Nagoya City, Aichi, Japan
Mitaka City, Tokyo, Japan
Hongkong, , Hong Kong
Muenster, , Germany
Chennai, Tamil Nadu, India
Madurai, Tamil Nadu, India
Bristol, , United Kingdom
Fukushima City, Fukushima, Japan
Banska Bystrica, Slovak Republic, Slovakia
Bielsko Biala, , Poland
Alicante, Comunidad Valenciana, Spain
Vancouver, British Columbia, Canada
Freiburg, , Germany
Mumbai, Maharashtra, India
New Delhi, , India
Linz, Upper Austria, Austria
Dijon, , France
Nuernberg, , Germany
Mumbai, Maharashtra, India
Bangalore, , India
Kita Gun, Kagawa, Japan
Matsumoto, Nagano, Japan
Hirakata City, Osaka, Japan
Chiyoda Ku, Tokyo, Japan
Kaunas, , Lithuania
Singapore, , Singapore
Bratislava, , Slovakia
Bilbao, Pais Vasco, Spain
Genève, , Switzerland
Lausanne, , Switzerland
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials